EyePoint Pharmaceuticals files $200 million common stock offering prospectus By Investing.com
EyePoint Pharmaceuticals files $200 million common stock offering prospectus…
16,660$
-1,59%
Echtzeit-Aktienkurs EyePoint Inc.
Bid:
Ask:
Nachrichten zur EyePoint Inc. Aktie
EyePoint Pharmaceuticals stock maintains Outperform rating at Mizuho By Investing.com
EyePoint Pharmaceuticals stock maintains Outperform rating at Mizuho…
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing…
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com
EyePoint Pharmaceuticals stock sinks following clinical trial results…
EyePoint Pharmaceuticals: Mit DURAVYU könnte man 40 % der Marktanteile im wAMD-Segment gewinnen!
EyePoint Pharmaceuticals Inc. (EYPT) hat sich auf Therapien zur Behandlung schwerer Netzhauterkrankungen spezialisiert. Im Fokus stehen zum Beispiel Lösungen für…
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
…
EyePoint Pharmaceuticals prices $140M share offering
…
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To Buy The Dip (Rating Upgrade)
…
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
Cormorant Asset Management buys $10.49m in EyePoint Pharmaceuticals shares By Investing.com
Cormorant Asset Management buys $10.49m in EyePoint Pharmaceuticals shares…
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
Earnings call: EyePoint Pharmaceuticals outlines growth and EYP-1901 progress By Investing.com
Earnings call: EyePoint Pharmaceuticals outlines growth and EYP-1901 progress…
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript
…
EyePoint Pharmaceuticals appoints new Chief Medical Officer By Investing.com
EyePoint Pharmaceuticals appoints new Chief Medical Officer…